旨在克隆牦牛胰岛素样生长因子结合蛋白4和5(insulin-like growth factor binding protein 4 and 5,IGFBP4 and IGFBP5)基因,并检测其在牦牛不同组织及不同生长阶段肝中的表达水平。本研究选取1日龄、15月龄和5岁龄健康雌性麦洼牦牛共9...旨在克隆牦牛胰岛素样生长因子结合蛋白4和5(insulin-like growth factor binding protein 4 and 5,IGFBP4 and IGFBP5)基因,并检测其在牦牛不同组织及不同生长阶段肝中的表达水平。本研究选取1日龄、15月龄和5岁龄健康雌性麦洼牦牛共9头(每组各3头),体重分别约为(12.35±1.85)、(98.88±2.50)和(268.55±27.82)kg,采集5岁龄牦牛心、肝、脾、肺、肾、小肠组织及3个不同生长阶段牦牛肝组织。本试验克隆IGFBP4和IGFBP5基因,并对其序列进行生物信息学分析,采用qRT-PCR方法、Western blot技术与免疫组化技术检测其在5岁龄牦牛6种组织及1日龄、15月龄和5岁龄3个不同生长阶段肝中的表达差异。结果表明,获得牦牛IGFBP4和IGFBP5基因的CDS序列分别为777和816 bp,分别编码258和271个氨基酸,GenBank序列号分别为MT012934和MT003005。在同源性比较中,牦牛IGFBP4和IGFBP5序列均与黄牛的同源性最高,分别为99.6%、99.5%。组织表达谱分析显示,IGFBP4和IGFBP5基因均在5岁龄牦牛肝中表达量最高,与肾、心、小肠、脾、肺相比差异极显著(P<0.01),且6种组织中IGFBP4基因的表达量均极显著高于IGFBP5基因(P<0.01)。不同生长阶段肝中差异表达结果显示,随着年龄的增长,IGFBP4和IGFBP5的mRNA与蛋白水平在牦牛肝脏组织中的表达量均呈现上升趋势,即5岁龄>15月龄>1日龄,在5岁龄时表达量最高,与1日龄和15月龄均存在极显著差异(P<0.01),且IGFBP4的表达量极显著高于IGFBP5(P<0.01)。结果提示,IGFBP4和IGFBP5可能协同调控牦牛肝的生长发育,这为深入研究IGFBP4和IGFBP5在牦牛肝生长发育过程中的作用以及表达调控提供了一定的基础数据。展开更多
Insulin-like growth factor-bindin g proteins (IGFBPs) are critical regulators of the mitogenic activity of insulin-like growth factors (IGFs). IGFBP5, one of these IGFBPs, has special structural features, including a ...Insulin-like growth factor-bindin g proteins (IGFBPs) are critical regulators of the mitogenic activity of insulin-like growth factors (IGFs). IGFBP5, one of these IGFBPs, has special structural features, including a nuclear transport domain, heparin-binding motif, and IGF/extracellular matrix/acid-labile subunit-binding sites. Furthermore, IGFBP5 has several functional effects on carcinogenesis and even normal cell processes, such as cell growth, death, motility, and tissue remodeling. These biological effects are sometimes related with IGF (IGF-dependent effects) and sometimes not (IGF-independent effects). The functional role of IGFBP5 is most likely determined in a cell-type and tissue-type specific manner but also depends on cell context, especially in terms of the diversity of interacting proteins and the potential for nuclear localization. Clinical findings show that IGFBP5 has the potential to be a useful clinical biomarker for predicting response to therapy and clinical outcome of cancer patients. In this review, we summarize the functional diversity and clinical importance of IGFBP5 in different types of cancers.展开更多
文摘旨在克隆牦牛胰岛素样生长因子结合蛋白4和5(insulin-like growth factor binding protein 4 and 5,IGFBP4 and IGFBP5)基因,并检测其在牦牛不同组织及不同生长阶段肝中的表达水平。本研究选取1日龄、15月龄和5岁龄健康雌性麦洼牦牛共9头(每组各3头),体重分别约为(12.35±1.85)、(98.88±2.50)和(268.55±27.82)kg,采集5岁龄牦牛心、肝、脾、肺、肾、小肠组织及3个不同生长阶段牦牛肝组织。本试验克隆IGFBP4和IGFBP5基因,并对其序列进行生物信息学分析,采用qRT-PCR方法、Western blot技术与免疫组化技术检测其在5岁龄牦牛6种组织及1日龄、15月龄和5岁龄3个不同生长阶段肝中的表达差异。结果表明,获得牦牛IGFBP4和IGFBP5基因的CDS序列分别为777和816 bp,分别编码258和271个氨基酸,GenBank序列号分别为MT012934和MT003005。在同源性比较中,牦牛IGFBP4和IGFBP5序列均与黄牛的同源性最高,分别为99.6%、99.5%。组织表达谱分析显示,IGFBP4和IGFBP5基因均在5岁龄牦牛肝中表达量最高,与肾、心、小肠、脾、肺相比差异极显著(P<0.01),且6种组织中IGFBP4基因的表达量均极显著高于IGFBP5基因(P<0.01)。不同生长阶段肝中差异表达结果显示,随着年龄的增长,IGFBP4和IGFBP5的mRNA与蛋白水平在牦牛肝脏组织中的表达量均呈现上升趋势,即5岁龄>15月龄>1日龄,在5岁龄时表达量最高,与1日龄和15月龄均存在极显著差异(P<0.01),且IGFBP4的表达量极显著高于IGFBP5(P<0.01)。结果提示,IGFBP4和IGFBP5可能协同调控牦牛肝的生长发育,这为深入研究IGFBP4和IGFBP5在牦牛肝生长发育过程中的作用以及表达调控提供了一定的基础数据。
基金supported partly by grants (SBAG-111S161 to MA) from the Scientific and Technological Reaserch Council of Türkiye (TUBITAK)(SAG-C-YLP-210311-0048 to MA) from the Reaserch Foundation of Marmara University (BAPKO)
文摘Insulin-like growth factor-bindin g proteins (IGFBPs) are critical regulators of the mitogenic activity of insulin-like growth factors (IGFs). IGFBP5, one of these IGFBPs, has special structural features, including a nuclear transport domain, heparin-binding motif, and IGF/extracellular matrix/acid-labile subunit-binding sites. Furthermore, IGFBP5 has several functional effects on carcinogenesis and even normal cell processes, such as cell growth, death, motility, and tissue remodeling. These biological effects are sometimes related with IGF (IGF-dependent effects) and sometimes not (IGF-independent effects). The functional role of IGFBP5 is most likely determined in a cell-type and tissue-type specific manner but also depends on cell context, especially in terms of the diversity of interacting proteins and the potential for nuclear localization. Clinical findings show that IGFBP5 has the potential to be a useful clinical biomarker for predicting response to therapy and clinical outcome of cancer patients. In this review, we summarize the functional diversity and clinical importance of IGFBP5 in different types of cancers.
